podophyllotoxin has been researched along with Disease Exacerbation in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M | 1 |
| Bissinger, M; Breuhahn, K; Ehemann, V; Gretz, N; Khamidjanov, A; Nussbaum, T; Ryschich, E; Samarin, J; Schirmacher, P; Yu, X | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Blokhin, DIu | 1 |
| Caidahl, K; Hedin, U; Lund, K; Razuvaev, A; Roy, J | 1 |
| Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M | 1 |
| Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
1 review(s) available for podophyllotoxin and Disease Exacerbation
| Article | Year |
|---|---|
[The multidrug tumor cell resistance phenotype caused by the impaired cell death program].
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, p53; Humans; Mitoxantrone; Neoplasms; Phenotype; Podophyllotoxin; Radiation Tolerance; Tumor Cells, Cultured | 2004 |
2 trial(s) available for podophyllotoxin and Disease Exacerbation
| Article | Year |
|---|---|
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia | 1996 |
6 other study(ies) available for podophyllotoxin and Disease Exacerbation
| Article | Year |
|---|---|
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
Topics: Animals; Autocrine Communication; Carcinoma, Hepatocellular; Cell Movement; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Podophyllotoxin; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 2008 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Noninvasive real-time imaging of intima thickness after rat carotid artery balloon injury using ultrasound biomicroscopy.
Topics: Animals; Carotid Arteries; Carotid Artery Injuries; Catheterization; Diagnostic Imaging; Disease Progression; Male; Microscopy, Acoustic; Observer Variation; Podophyllotoxin; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Tunica Intima; Ultrasonics | 2008 |
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |